Zhan Y.,Twelfth Guangzhou Municipal People s Hospital |
Chen J.-y.,Twelfth Guangzhou Municipal People s Hospital |
Chen L.-z.,Twelfth Guangzhou Municipal People s Hospital |
Yu W.,Twelfth Guangzhou Municipal People s Hospital |
And 4 more authors.
Journal of Leukemia and Lymphoma | Year: 2012
Objective To explore the efficacy and safety of bone marrow mesenchymal stem cells (BMSC) in treatment of aplastic anemia (AA). Methods Twenty-two patients with aplastic anemia were enrolled with median age of 31 (12-70) years old, including 11 severe aplastic anemia (SAA), and 3 of whom were cyclosporine and anti-thymocyte globulin-resistant. BMSC were isolated from bone marrow of healthy donors and cultured. The third to fifth generation cells were administered intravenously in 1×106/kg to patients once or twice a week. After infusion, complete blood count, bone marrow aspiration, bone marrow biopsy, flow cytometry analysis of lymphocyte subsets of CD+ 3 CD+ 4 and CD+ 3 CD+ 8 and clinical symptoms were involved in outcome measurement. Results All patients finished 16-time median (5-83 times) infusions of BMSC with 13-month median (2-33 months) treatment course and 23-month median (2-34 months) follow-up. The total response rate was 72.7% (16/22), including one patient with essential cure, 9 with remission, 3 with remarkably improvement and 3 with transfusion interval extension. Two of three front-line immunosuppressive- resistant SAA patients achieved remission. Ten of 14 patients recovered from inverted ratio of CD+ 4 /CD+ 8 cells after BMSC treatment. There were no treatment-related side effects observed in the course of treatment. Conclusion BMSC are effective and safe for the treatment of AA in our preliminary study and they deserve further research with larger-scale and long-term clinical trials.